Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

The crimes reportedly happened at a Loganville home in February of 2020. Abraham Quintanar, Miguel Angel Gonzalez, and ...

Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

Before Gilead’s rise, the world in The Handmaid’s Tale was already falling apart. Food shortage, political unrest, environmental disasters — it was all there, bubbling just under the surface.

Given that there is no confirmed CDC director and a small newly appointed panel with many members lacking a broad vaccine or immunology knowledge, “there are concerns about the rushed nature of this ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Gilead Sciences, Inc. (GILD) said on Wednesday that it entered into an exclusive option and license agreement with biotech ...

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to ...

Gilead’s HIV treatment trials involving GS-1720 and GS-4182 have been put on clinical hold by the Food and Drug Administration.

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...